Evolent Health, Inc.
NYSE:EVHMedical - Healthcare Information Services
-$0.28 today
- Market cap
- $442.05M
- Beta
- 0.83
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.44
Volume 3.10M
Average 2.78M
EVH Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Evolent Health, Inc.NYSE: EVH
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $4.3M (cash outflow) fell 72.8% year over year, behind the +3185.5% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 3.9% of revenue in FY2025, up 2.7 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -72.8% toward the trailing-twelve-month pace of +3185.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 73.7M USD
- Year-over-year change
- +129.9%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.7M | +129.9% |
| FY2024 | 2024-12-31 | 32.06M | +119.5% |
| FY2023 | 2023-12-31 | (164.69M) | -59.9% |
| FY2022 | 2022-12-31 | (102.98M) | -315.9% |
| FY2021 | 2021-12-31 | (24.76M) | — |
Accounts Receivables vs competitors
How EVH compares with its peers on the latest reported figures
- EVH's LTM Mar 2026 accounts receivables of $85.22M is the largest of the 11 companies compared; the peer median is $2.67M.
- Its year-over-year change of +3185.5% is the highest of 10, against a peer median of -76.5%.
- Accounts receivables amounts to 4.5% of revenue for EVH, versus a peer median of 4.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $85.22M | +3185.5% | — | 4.5% | |
| LTM Mar 2026 | $46.51M | -80.1% | — | 5.3% | |
| LTM Mar 2026 | $41.69M | -76.5% | +55.1% | 1.2% | |
| LTM Mar 2026 | $39.4M | +184.4% | — | 55.0% | |
| LTM Mar 2026 | $13.03M | -178.8% | — | 16.3% | |
| LTM Mar 2026 | $7.53M | -241.6% | -20.0% | 2.4% | |
| LTM Mar 2026 | $6.2M | -10.1% | +30.2% | 6.0% | |
| LTM Mar 2026 | $3.3M | -17.5% | -7.0% | 0.4% | |
| LTM Mar 2026 | $2.05M | -650.8% | — | 3.2% | |
| LTM Dec 2025 | $354K | -70.4% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding EVH) | $2.67M | -76.5% | +11.6% | 4.2% | |
Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (37.6M) | (19.16M) | (113.04M) | (61.62M) | (579.4M) |
| Depreciation & Amortization | 60.04M | 67.2M | 123.42M | 125.62M | 122.65M |
| Deferred Income Tax | (526K) | 342K | (31.27M) | (2.82M) | (2.98M) |
| Stock-Based Compensation | 16.71M | 33.98M | 40.5M | 39.75M | 39.74M |
| Change in Working Capital | (22.49M) | (104.44M) | 21.89M | (116.56M) | (57.38M) |
| Accounts Receivables | (24.76M) | (102.98M) | (164.69M) | 32.06M | 73.7M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.25M | 13.17M | (6.72M) | 4.25M | 6.64M |
| Other Working Capital | (4.98M) | (14.63M) | 193.31M | (152.87M) | (137.73M) |
| Other Non-Cash Items | 22.62M | 10.53M | 101.09M | 34.4M | 516.23M |
| Operating Cash Flow | 38.75M | (11.55M) | 142.58M | 18.77M | 38.84M |
| Capital Expenditures | (24.98M) | (38.36M) | (28.75M) | (24.89M) | (34.09M) |
| Acquisitions (Net) | 14.22M | 5.55M | 870K | (30.73M) | (57.44M) |
| Purchases of Investments | (3M) | (5.55M) | 0 | (7.32M) | (1M) |
| Sales of Investments | 500K | 5.55M | 0 | 7K | 986K |
| Other Investing Activities | (2.53M) | (226.31M) | (387.67M) | 0 | 91.31M |
| Investing Cash Flow | (15.79M) | (259.12M) | (415.54M) | (62.93M) | (233K) |
| Debt Repayment | (37.69M) | 219.74M | 183.29M | 58.58M | 65.06M |
| Common Stock Issued | 13.29M | 4.45M | 180.52M | 3.46M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (40M) |
| Dividends Paid | (1.3M) | (14.88M) | (18.79M) | (20.09M) | (11.13M) |
| Other Financing Activities | (3.85M) | (77.77M) | (63.68M) | (42.52M) | (49.86M) |
| Financing Cash Flow | (29.55M) | 131.54M | 281.34M | (565K) | (35.92M) |
| Effect of Forex Changes | (52K) | (657K) | (79K) | (229K) | 11.81M |
| Net Change in Cash | (6.64M) | (139.78M) | 8.3M | (44.96M) | 14.49M |
| Free Cash Flow | 13.76M | (49.91M) | 113.84M | (6.13M) | 4.76M |
Evolent Health, Inc.
NYSE:EVH
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.